Literature DB >> 2759204

Antiarrhythmic peptide has no direct cardiac actions.

T Argentieri1, E Cantor, J R Wiggins.   

Abstract

The electrophysiologic, inotropic, and muscarinic effects of antiarrhythmic peptide (AAP) were examined in canine cardiac Purkinje fibers, ferret papillary muscle, and canine cardiac membranes, respectively. Aside from a prolongation of time to peak force in papillary muscle, no biologically significant effects of AAP could be determined in any preparation, suggesting that its antiarrhythmic effects are not mediated by direct membrane actions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2759204     DOI: 10.1007/BF01974573

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


  7 in total

1.  Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents.

Authors:  W C Lumma; R A Wohl; D D Davey; T M Argentieri; R J DeVita; R P Gomez; V K Jain; A J Marisca; T K Morgan; H J Reiser
Journal:  J Med Chem       Date:  1987-05       Impact factor: 7.446

2.  Central neurotransmitter receptors in hypertensive rats.

Authors:  E H Cantor; S Abraham; S Spector
Journal:  Life Sci       Date:  1981-02-02       Impact factor: 5.037

3.  Studies on heart. XXIV. Inhibitory effect of antiarrhythmic peptide (AAP) on experimental thromboses.

Authors:  S Aonuma; Y Kohama; T Makino; K Hattori; Y Kawahara
Journal:  Chem Pharm Bull (Tokyo)       Date:  1984-01       Impact factor: 1.645

4.  Studies on heart. XIX. Isolation of an atrial peptide that improves the rhythmicity of cultured myocardial cell clusters.

Authors:  S Aonuma; Y Kohama; K Akai; Y Komiyama; S Nakajima; M Wakabayashi; T Makino
Journal:  Chem Pharm Bull (Tokyo)       Date:  1980-11       Impact factor: 1.645

5.  Studies on heart. II. Further effects of bovine ventricle protein (BVP) and antiarrhythmic peptide (AAP) on myocardial cells in culture.

Authors:  S Aonuma; Y Kohama; K Akai; S Iwasaki
Journal:  Chem Pharm Bull (Tokyo)       Date:  1980-11       Impact factor: 1.645

6.  Cardiotonic agents. 2. (Imidazolyl)aroylimidazolones, highly potent and selective positive inotropic agents.

Authors:  A A Hagedorn; P W Erhardt; W C Lumma; R A Wohl; E Cantor; Y L Chou; W R Ingebretsen; J W Lampe; D Pang; C A Pease
Journal:  J Med Chem       Date:  1987-08       Impact factor: 7.446

7.  Response of immunoreactive antiarrhythmic peptide (IR-AAP) level associated with experimental arrhythmia in rats.

Authors:  Y Kohama; K Iwabuchi; T Shibahara; M Okabe; T Mimura
Journal:  J Pharmacobiodyn       Date:  1986-10
  7 in total
  3 in total

Review 1.  Increasing gap junctional coupling: a tool for dissecting the role of gap junctions.

Authors:  Lene Nygaard Axelsen; Ketil Haugan; Martin Stahlhut; Anne-Louise Kjølbye; James K Hennan; Niels-Henrik Holstein-Rathlou; Jørgen Søberg Petersen; Morten Schak Nielsen
Journal:  J Membr Biol       Date:  2007-06-14       Impact factor: 1.843

Review 2.  Therapeutic potential of antiarrhythmic peptides. Cellular coupling as a new antiarrhythmic target.

Authors:  S Dhein; T Tudyka
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

3.  A new synthetic antiarrhythmic peptide reduces dispersion of epicardial activation recovery interval and diminishes alterations of epicardial activation patterns induced by regional ischemia. A mapping study.

Authors:  S Dhein; N Manicone; A Müller; R Gerwin; U Ziskoven; A Irankhahi; C Minke; W Klaus
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-08       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.